Hormone dynamics, pharmacokinetics, safety and efficacy of leuprorelin acetate 6-month depot formulation and tamoxifen adjuvant endocrine therapy combination in premenopausal patients with hormone receptor-positive breast cancer

被引：0
|
作者：
Kurebayashi, J.
Toyama, T.
Sumino, S.
Fujimoto, T.
机构：
[1] Kawasaki Med Sch, Kurashiki, Okayama, Japan
[2] Nagoya City Univ Hosp, Nagoya, Aichi, Japan
[3] Takeda Pharmaceut Co Ltd, Osaka, Japan
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-12-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-12-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients
    Shimizu, Daisuke
    Ishikawa, Takashi
    Tanabe, Mikiko
    Sasaki, Takeshi
    Ichikawa, Yasushi
    Chishima, Takashi
    Endo, Itaru
    BREAST CANCER, 2014, 21 (05) : 557 - 562
  • [2] Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients
    Daisuke Shimizu
    Takashi Ishikawa
    Mikiko Tanabe
    Takeshi Sasaki
    Yasushi Ichikawa
    Takashi Chishima
    Itaru Endo
    Breast Cancer, 2014, 21 : 557 - 562
  • [3] Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
    Wu, Zhen-Yu
    Lee, Young-jin
    Kim, Heejeong
    Lee, Jongwon
    Chung, Il Yong
    Kim, Jisun
    Lee, Saebyeol
    Son, Byung-Ho
    Kim, Sung-Bae
    Jeong, Jae Ho
    Gong, Gyungyub
    Ahn, Sei-Hyun
    Ko, BeomSeok
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Preoperative Endocrine Therapy with Tamoxifen and Goserelin Acetate for Hormone Receptor-Positive Premenopausal Patients
    Shimizu, D.
    Ishikawa, T.
    Yamada, A.
    Tanaabe, M.
    Chishima, T.
    Sasaki, T.
    Endo, I.
    CANCER RESEARCH, 2010, 70
  • [5] Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer
    Tevaarwerk, Amye J.
    Wisinski, Kari B.
    O'Regan, Ruth M.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1148 - +
  • [6] Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study
    Junichi Kurebayashi
    Tatsuya Toyama
    Shuuji Sumino
    Eri Miyajima
    Tsukasa Fujimoto
    Breast Cancer, 2017, 24 : 161 - 170
  • [7] Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study
    Kurebayashi, Junichi
    Toyama, Tatsuya
    Sumino, Shuuji
    Miyajima, Eri
    Fujimoto, Tsukasa
    BREAST CANCER, 2017, 24 (01) : 161 - 170
  • [8] Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Ozdemir, Nuriye Y.
    Zengin, Nurullah
    Yazici, Ozan
    Sever, Ali R.
    Altundag, Kadri
    JOURNAL OF BUON, 2016, 21 (01): : 27 - 34
  • [9] Efficacy of adjuvant tamoxifen in hormone receptor-positive premenopausal breast cancer patients according to the body mass index
    Altundag, Kadri
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Ozisik, Yavuz
    CANCER RESEARCH, 2015, 75
  • [10] Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe
    U W Tunn
    K Wiedey
    Prostate Cancer and Prostatic Diseases, 2009, 12 : 83 - 87
12345